(Press-News.org) Oxford, August 29, 2012 - The Moon is believed to have formed from a collision, 4.5 billion years ago, between Earth and an impactor the size of Mars, known as "Theia." Over the past decades scientists have simulated this process and reproduced many of the properties of the Earth-Moon system; however, these simulations have also given rise to a problem known as the Lunar Paradox: the Moon appears to be made up of material that would not be expected if the current collision theory is correct. A recent study published in Icarus proposes a new perspective on the theory in answer to the paradox.
If current theories are to be believed, analyses of the various simulations of the Earth-Theia collision predict that the Moon is mostly made up of material from Theia. However, studying materials from both Earth and the Moon, shows remarkable similarities. In fact, elements found on the Moon show identical isotopic properties to those found on Earth.
Given it is very unlikely that both Theia and Earth had identical isotopic compositions (as all other known solar system bodies, except the Moon, appear to be different) this paradox casts doubt over the dominant theory for the Moon formation. Moreover, for some elements, like Silicon, the isotopic composition is the result of internal processes, related to the size of the parent body. Given Theia was smaller than Earth, its Silicon isotope composition should have definitely been different from that of Earth's mantle.
A group of researchers from the University of Bern, Switzerland, have now made a significant breakthrough in the story of the formation of the Moon, suggesting an answer to this Lunar Paradox. They explored a different geometry of collisions than previously simulated, also considering new impacts configurations such as the so-called, "hit-and-run collisions," where a significant amount of material is lost into space on orbits unbound to the Earth.
"Our model considers new impact parameters, which were never tested before. Besides the implications for the Earth-Moon system itself, the considerably higher impact velocity opens up new possibilities for the origin of the impactor and therefore also for models of terrestrial planet formation," explains lead author of the study, Andreas Reufer.
"While none of the simulations presented in their research provides a perfect match for the constraints from the actual Earth-Moon-system, several do come close," adds Alessandro Morbidelli, one of the Icarus' Editors. "This work, therefore, suggests that a future exhaustive exploration of the vast collisional parameter space may finally lead to the long-searched solution of the lunar paradox."
###
The article "A hit-and-run Giant Impact scenario" by Andreas Reufer, Matthias M.M. Meier, Willy Benz, Rainer Wieler (doi:10.1016/j.icarus.2012.07), appears in Icarus, published by Elsevier. To view the article online, click here, or contact newsroom@elsevier.com for the full text.
Notes for editors
To view the article online, click here, or contact newsroom@elsevier.com; journalists wishing to interview the authors, please contact Clare Lehane at +44 1865 843466 c.lehane@elsevier.com.
About Icarus
Icarus is devoted to the publication of original contributions in the field of Solar System studies. Manuscripts reporting the results of new research - observational, experimental, or theoretical - concerning the astronomy, geology, meteorology, physics, chemistry, biology, and other scientific aspects of our Solar System or extra solar systems are welcome. Icarus is the official publication of American Astronomical Society's Division for Planetary Sciences and follows the APB publishing process.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close
to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of
science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Clare Lehane
Elsevier
+44 1865 843466
c.lehane@elsevier.com
Implantable devices for treating cardiac arrhythmias, which include ICDs, are already underused in parts of Eastern and Central Europe and there is a risk that the financial crisis could exacerbate the problem. The European Heart Rhythm Association (EHRA), a registered branch of the ESC, is tackling this issue through ICD for Life. The initiative aims to raise awareness about the importance of ICDs and sudden cardiac death in countries in Central and Eastern Europe.
ICD implantation rates in Europe vary widely, ranging from 1 ICD implantation per million inhabitants in ...
The 2012 expert consensus statement on catheter and surgical ablation of atrial fibrillation was developed by the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and the European Cardiac Arrhythmia Society (ECAS) and published in their respective journals: Heart Rhythm, EP Europace (1) and the Journal of Interventional Cardiovascular Electrophysiology (JICE).
Since the previous consensus document was published in 2007 catheter and surgical ablation of AF have become standard treatments ...
Aplastic anaemia is characterised by a reduction in the number of the bone marrow cells that go on to form the different cell types present in blood (essentially red blood cells, white blood cells and platelets). In most cases, the causes of the disorder are hard to determine, but some patients have been found to have genetic alterations leading to a shortening of their telomeres (the end regions of chromosomes that protect and stabilise DNA).
A team at the Spanish National Cancer Research Centre (CNIO) led by María Blasco has successfully created a transgenic mouse model ...
KANSAS CITY, MO—As the national waistline expands, so do pools of intra-cellular fat known as lipid droplets. Although most of us wish our lipid droplets would vanish, they represent a cellular paradox: on the one hand droplets play beneficial roles by corralling fat into non-toxic organelles. On the other, oversized lipid droplets are associated with obesity and its associated health hazards.
Until recently researchers understood little about factors that regulate lipid droplet size. Now, a study from the Stowers Institute of Medical Research published in an upcoming ...
ANN ARBOR, Mich.—Rising sea levels, melting glaciers, more intense rainstorms and more frequent heat waves are among the planetary woes that may come to mind when climate change is mentioned. Now, two University of Michigan researchers say an increased risk of avian influenza transmission in wild birds can be added to the list.
Population ecologists Pejman Rohani and Victoria Brown used a mathematical model to explore the consequences of altered interactions between an important species of migratory shorebird and horseshoe crabs at Delaware Bay as a result of climate ...
The analysis was conducted using five editions of the EHRA White Book, which is produced by the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC).
The EHRA White Book reports on the current status of arrhythmia treatments in the 54 ESC member countries and has been published every year since 2008. Data is primarily provided by the national cardiology societies and working groups of cardiac pacing and electrophysiology of each ESC country. Prospective data is collected on catheter ablation and on implantation of cardiovascular ...
The registry is part of the European Society of Cardiology (ESC) EURObservational Research Programme (EORP) of surveys and registries.
Today's presentation reveals current usage of the most modern TAVI valves and catheters in Europe, and compares indications, techniques and outcomes between different countries. "TAVI is a new technology which has been introduced in Europe but many question marks remain on which patients are most suitable," said Professor Di Mario. "We set up this registry because it was important to have a clear picture of clinical practice in Europe. ...
Fampridine (trade name Fampyra®) has been approved in Germany since July 2011 for adult patients suffering from a higher grade walking disability (grades 4 to 7 on the EDSS disability status scale), as a result of multiple sclerosis (MS). The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, there is no proof of added benefit, as the manufacturer's dossier contains no evaluable study data for the comparison ...
ANN ARBOR, Mich. — A drug originally developed to stop cancerous tumors may hold the potential to prevent abnormal brain cell growth and learning disabilities in some children, if they can be diagnosed early enough, a new animal study suggests.
The surprising finding sets the stage for more research on how anti-tumor medication might be used to protect the developing brains of young children with the genetic disease neurofibromatosis 1 -- and other diseases affecting the same cellular signaling pathway.
The findings, made in mice, are reported in the journal Cell ...
Belimumab (trade name Benlysta ®) has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). This monoclonal antibody is only considered as treatment when the disease is still active in spite of standard therapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of this drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG).
According to the findings, there is no proof that belimumab provides added benefit ...
